

**How to
 Use This
 Document**

This document is intended to summarize updates to the Wellfleet Rx National Preferred Formulary that will go into effect as of 1/1/2022. Members with current utilization for any negatively affected medications listed below will be notified of upcoming changes in October 2021 and will not be grandfathered. For and new utilizers as of late 2021, grandfathering will be applied until 4/1/2022.

Positive Changes Effective 1/1/2022 for All Users

Move to Preferred Status

Drug Class	Drug	Rationale
Immunomodulator	BENLYSTA SQ AUTO INJECT/SYRINGE	Clinical/Safety Strategy
HCV Antivirals	HARVONI 33.75-150 MG/45 – 200 MG PACKET (PA)	Clinical/Safety Strategy
Multiple Sclerosis Agent	PONVORY	Trade Relations Strategy
Cardiovascular Disease	DROXIDOPA	Low Net Cost Strategy
Hemostatics	SEVENFACT	Trade Relations Strategy
Anti-Inflammatory Agents	APRISO	Trade Relations Strategy
Diabetic – Insulin	LYUMJEV	Trade Relations Strategy
Diabetes – SGLT2 Combo	TRIJARDY	Trade Relations Strategy
Diabetes – GLP1-RA	VICTOZA	Trade Relations Strategy
Diabetic Supplies	OMNIPOD & OMNIPOD DASH/V-GO	Trade Relations Strategy
Growth Hormones	OMNITROPE	Trade Relations Strategy
Diabetic Supplies	BD INSULIN SYRINGE CLEAN UP (MULTIPLE NDCS)	Clinical/Safety Strategy
Weight Loss	SAXENDA, WEGOVY, QSYMIA	Clinical/Safety/Trade Relations
Gout	COLCHICINE TABLETS	Trade Relations Strategy
Cystic Fibrosis	SYMDEKO/TRIKAFTA	Low Net Cost Strategy

Remove Prior Authorization Status

Diabetic Supplies	DEXCOM & FREESTYLE LIBRE/LIBRE 2 READER & METER	Clinical/Safety Strategy
Dermatology	TRETINOIN	Clinical/Safety Strategy

Remove Specialty Drug Status

Behavioral Health	LONG-ACTING INJECTABLE ANTIPSYCHOTICS (ABILIFY MAINTENA, ARISTADA, INVEGA SUSTENNA/TRINZA, RISPERDAL CONSTA, ZYPREXA RELPREVV, PERSERIS, FLUPHENAZINE DECANOATE)	Clinical/Safety Strategy
Antiviral/HBV	VEMLIDY	Clinical/Safety Strategy

Viscoelastic Substances	ORTHOVISC, MONOVISC, EUFLEXXA	Clinical/Safety Strategy
Update Quantity Limit		
Inhaled Steroid/LABA	SYMBICORT 80-4.5 mcg	Clinical/Safety Strategy

**Negative Changes –
Effective 4/1/2022 for New Users
Effective 1/1/2022 for Existing Users**

Add Step Therapy		
Anti-Alzheimer Agent	MEMANTINE HCL ER	Low Net Cost Strategy
Dermatology	FLURANDRENOLIDE 0.5% OINTMENT ALA-SCALP 2% LOTION HYDROCORTISONE VALERATE 0.2% OINTMENT	Low Net Cost Strategy
Move to Non-Preferred		
Antineoplastics	SUTENT	Low Net Cost Strategy
Add Prior Authorization		
Metabolic Disorder Agent	NULIBRY	Clinical/Safety Strategy
Immunomodulator	BENLYSTA IV VIAL	Clinical/Safety Strategy
Copper Chelating Agent	TRIENTINE	Clinical/Safety Strategy
Antiemetic	SANCUSO	Clinical/Safety Strategy
Infectious Disease	IMPAVIDO POSACONAZOLE	Clinical/Safety Strategy
Pain Management	MORPHINE SULFATE SOLUTION 100MG/5ML	Clinical/Safety Strategy
Pain Management	OXYCODONE ORAL CONCENTRATE 20MG/ML	Clinical/Safety Strategy
Add Quantity Limit		
Skeletal Muscle Relaxants	SKELETAL MUSCLE RELAXANTS CLASS	Clinical Safety/Low Net Cost Strategy
Eye – General Disorders	CROMOLYN SODIUM OPHTHALMIC DROPS DEXAMETHASONE 0.1% EYE DROPS EPINASTINE 0.05% EYE DROPS FLUOROMETHALONE 0.1% EYE DROPS PREDNISOLONE 1% OPHTHALMIC DROPS	Clinical Safety/Low Net Cost Strategy
Infectious Disease - Parasitic	NITAZOXANIDE 500 MG TABLETS	Clinical Safety/Low Net Cost Strategy
Dermatology - Topical	GENTAMICIN 0.1% TOPICAL OINTMENT HYDROCORTISONE BUTYRATE 0.1% LOTION MUPIROCIN 2% TOPICAL OINTMENT NYSTATIN TOPICAL OINTMENT NYSTATIN/TRIAMCINOLONE TOPICAL OINTMENT TRIMACINOLONE ACETONIDE 0.5% CREAM	Clinical Safety/Low Net Cost Strategy
Move to Excluded		
Viscoelastic Substances	HYALURONATE PRODUCTS	Trade Relations Strategy
Dyslipidemia Agents	ICOSAPENTH ETHYL 1 GRAM	Trade Relations Strategy

Antihypertensives	NISOLDIPINE ER	Low Net Cost Strategy
Hemostatics	NOVOSEVEN RT	Trade Relations Strategy
Diabetes – Insulin	BASAGLAR	Trade Relations Strategy
Diabetic Products	OLD KROGER BRAND BLOOD GLUCOSE STRIPS GAURDIAN LINK SENSOR/TRANSMITTER	Low Net Cost Strategy
Diabetes – SGLT2	INVOKANA, INVOKAMET/INVOKAMET ER, STEGLATRO, SEGLUROMET	Trade Relations Strategy
Growth Hormones	NORDITROPIN	Trade Relations Strategy
Topical Acne Agents	BENZEPRO 6% FOAMING CLOTHS/BPO	Low Net Cost Strategy
Behavioral Health	DESVENLAFASINE – 63304019130, 63304019230	Low Net Cost Strategy
Gout	COLCRYS, MITIGARE	Trade Relations Strategy
Copper Chelating Agents	DEPEN TABLETS, PENICILLAMINE CAPSULES	Low Net Cost Strategy
Miscellaneous	AFNITOR, KUVAN, LEXIVA, REMODULIN, REVATIO, TEMODAR, TRACLEER, TYKERB, ACULAR, ACULAR LS, ARAVA, ATROVENT, AVIDOXY, AYGESTIN, AZULFIDINE, BACIGUENT, BUPHENYL, CANASA, CARAGATE, CLASSIC PRENATAL, CLOZARIL, COMBIVIR, DARAPRIM, DIOVAN, DIOVAN HCT, EPZICOM, EVISTA, FEOSOL, FLOMAX, GELFOAM, GELFOAM COMPRESSED, GOPRELTO, IMURAN, KERYDIN, LASIX, LOFIBRA, MAVIX, MAXITROL, MS CONTIN, NITRO-DUR, PREVIDENT 5000 ENAMEL PROTECT/SENSITIVE, PROVERA, RELAFEN, SKELAXIN, TAPAZOLE, XOPENEX, XYZAL, ZOFRAN, ZOFRAN ODT, ZYLOPRIM	Low Net Cost Strategy

Please note: The bolded medications are brands with a generic available.

RATIONALE OF CHANGES

Trade Relations Strategy

Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.

Low Net Cost Strategy

Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.

Clinical/Safety Strategy

Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).

Regulatory Update

Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.